Home  »  Companies   »  Daily High to Daily Low: Is It Safe to Buy CTI Bio...

Daily High to Daily Low: Is It Safe to Buy CTI BioPharma Corp. (CTIC)?

CTI BioPharma Corp. (NASDAQ:CTIC) went down by -5.82% from its latest closing price compared to the recent 1-year high of $7.80. The company’s stock price has collected -8.04% of loss in the last five trading sessions.

Is It Worth Investing in CTI BioPharma Corp. (NASDAQ :CTIC) Right Now?

Plus, the 36-month beta value for CTIC is at 0.89. Opinions of the stock are interesting as 8 analysts out of 8 who provided ratings for CTI BioPharma Corp. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $10.74, which is $4.91 above the current price. CTIC currently public float of 114.17M and currently shorts hold a 13.81% ratio of that float. Today, the average trading volume of CTIC was 4.84M shares.

CTIC’s Market Performance

CTIC stocks went down by -8.04% for the week, with a monthly drop of 0.00% and a quarterly performance of 0.52%, while its annual performance rate touched 92.41%. The volatility ratio for the week stands at 6.76% while the volatility levels for the past 30 days are set at 6.60% for CTI BioPharma Corp. The simple moving average for the period of the last 20 days is -6.42% for CTIC stocks with a simple moving average of 31.53% for the last 200 days.

Analysts’ Opinion of CTIC

Many brokerage firms have already submitted their reports for CTIC stocks, with Jefferies repeating the rating for CTIC by listing it as a “Buy.” The predicted price for CTIC in the upcoming period, according to Jefferies is $13 based on the research report published on September 01st of the current year 2022.

Cowen, on the other hand, stated in their research note that they expect to see CTIC reach a price target of $10. The rating they have provided for CTIC stocks is “Outperform” according to the report published on July 07th, 2022.

BTIG Research gave a rating of “Buy” to CTIC, setting the target price at $7 in the report published on August 09th of the previous year.

CTIC Trading at -8.22% from the 50-Day Moving Average

After a stumble in the market that brought CTIC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.26% of loss for the given period.

Volatility was left at 6.60%, however, over the last 30 days, the volatility rate increased by 6.76%, as shares surge +4.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.89% lower at present.

During the last 5 trading sessions, CTIC fell by -8.04%, which changed the moving average for the period of 200-days by +159.11% in comparison to the 20-day moving average, which settled at $6.24. In addition, CTI BioPharma Corp. saw 135.08% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CTIC starting from Craig Adam R, who sale 242,300 shares at the price of $6.43 back on Sep 12. After this action, Craig Adam R now owns 27,861 shares of CTI BioPharma Corp., valued at $1,557,989 using the latest closing price.

Craig Adam R, the President and CEO of CTI BioPharma Corp., purchase 5,000 shares at $5.50 during a trade that took place back on Aug 16, which means that Craig Adam R is holding 27,861 shares at $27,500 based on the most recent closing price.

Stock Fundamentals for CTIC

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.

Is Cadence Bank (CADE) a Keeper?

Cadence Bank (NYSE:CADE) went down by -0.52% from its latest closing price compared to the recent 1-year high of $34.24. The company’s stock price has